Select Bibliography

Filter by any of these (after searching):

NCCTG-N0426

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 3 items

A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study.

Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - ASCO - J Clin Oncol - 2008

Abstract - Primary - Primary - Respiratory - NCCTG-N0426

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426

Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J Clin Oncol - 2010

Manuscript - Primary - Primary - Respiratory - NCCTG-N0426

Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer

Qi, Y. , Ziegler, K. L. Allen , Hillman, S. L. , Redman, M. W. ... - - Cancer - 2012

Manuscript - Secondary-not-in-original - Comprehensive - Respiratory - NCCTG-N0022 , NCCTG-N0026 , NCCTG-N0222 , NCCTG-N0323 , NCCTG-N0326 , NCCTG-N0426 , NCCTG-N0528 , NCCTG-N0626 , NCCTG-N0821 , NCCTG-N9921